03/18/2024

Anapharm Bioanalytics Brazilian ANVISA Certificate Renewal

SHARE

Anapharm Bioanalytics is proud to announce that it has recently renewed its ANVISA (Brazil) certification which is now valid until February 26th, 2024.

Anapharm has been certified by Brazilian regulatory authority since the first inspection took place in 2011. We have since then been supporting our European and Latin American customers achieving their goals in Brazilian market and will gladly continue our mission of providing high-quality bioanalytical services in the coming years.
Should you have any project that might require our bioanalytical support, please do not hesitate to contact our Business Development team, at contact@anapharmbioanalytics.com.

About Anapharm Bioanalytics

Anapharm is an in-vivo focused bioanalytical CRO with 30+ years’ experience and an outstanding regulatory track record in providing small and large molecule bioanalysis – from early discovery throughout preclinical GLP and clinical Phase I-III – covering PK, biomarker testing, ADA/immunogenicity assessment and cell-based assays.
We have facilities located in Barcelona that have 15 LC-MS/MS platforms for high throughput bioanalysis of small molecules and, to date, our team of experts has developed 600+ customized bioanalytical methods.
Our large molecule bioanalysis team has 20+ years’ experience in Ligand Binding Assays and has worked on 50+ antibody programs including mAb, Fab, bispecific, ADC and biosimilars, as well as fusion proteins, recombinant proteins, vaccines and gene therapy projects.
In addition Anapharm can support your Phase I-II-III clinical trial logistics with preparation and delivery of clinical kits to the sites, as well as transportation of biological samples from clinical sites to bioanalytical lab(s).